Bifidobacterium breve VPro 52 and Improved Growth Metrics

• Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study

  • 2019-11-20
  • RCT · n = 359
  • Journal of Nutritional Science 5
  • • M. Abrahamse-Berkeveld
    • M. Alles
    • E. Franke-Beckmann
    • K. Helm
    • R. Knecht
    • R. Köllges
    • B. Sandner
    • J. Knol
    • K. Ben Amor
    • A. Bufe

  • PubMed: 28620469
  • DOI: 10.1017/jns.2016.35

  9 Insights on

  • Improved Growth Metrics

  • High evidence
  • Large Human Trial

  Equivalence in daily weight gain was demonstrated for the intention-to-treat (ITT) population (n 211). In the per-protocol (PP) population (n 102), the 90 % CI of the difference in daily weight gain slightly crossed the lower equivalence margin. During the intervention period, the mean weight-for-age and length-for-age values were close to the median of the WHO growth standards in both groups, indicating adequate growth.

  Effect

  Beneficial

  Effect size

  Moderate